Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/George Farmer
SCOT
George Farmer
Wall Street Analyst
★★★☆☆
#1221
on 13Foresight · ranked by our own returns
61%
Success Rate
+22.2%
Average Return
20 of 33 calls profitable · -1.3% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 61% of George Farmer's ratings turned a profit when each position was held for 1 year — averaging +22.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

12 Buy 5 Hold 2 Sell
George's Stock Coverage 34 ratings · 2026-06-18
Company Date Position Consensus Price Target 1-Yr Return
NAMS
NewAmsterdam Pharma Company
Aug 07, 2025 BUY Strong Buy
+54.8% avg upside
18 analysts
$52.00
75.05% Upside
+29.9%
BMEA
Biomea Fusion
Aug 06, 2025 BUY Strong Buy
+1020.0% avg upside
15 analysts
$10.00
740.38% Upside
-8.2%
URGN
Urogen Pharma
Aug 06, 2025 BUY Strong Buy
+15.4% avg upside
16 analysts
$47.00
44.08% Upside
+52.2%
SNDX
Syndax Pharmaceuticals
Aug 05, 2025 HOLD Strong Buy
+87.3% avg upside
27 analysts
$17.00
11.32% Downside
+45.7%
BMRN
BioMarin Pharmaceutical
Aug 05, 2025 HOLD Strong Buy
+71.7% avg upside
52 analysts
$80.00
45.68% Upside
-11.2%
BIIB
Biogen
Aug 01, 2025 BUY Strong Buy
+24.4% avg upside
51 analysts
$224.00
15.32% Upside
+50.6%
ARGX
Argenx Se
Aug 01, 2025 BUY Strong Buy
-16.4% avg upside
46 analysts
$796.00
8.44% Downside
+31.0%
INMB
Inmune Bio
Jul 30, 2025 SELL Buy
+834.0% avg upside
11 analysts
$0.60
54.97% Downside
+53.7%
JANX
Janux Therapeutics Inc
Jul 25, 2025 HOLD Strong Buy
+220.6% avg upside
21 analysts
$36.00
158.14% Upside
-45.5%
LEGN
Legend Biotech
Jul 17, 2025 BUY Strong Buy
+115.9% avg upside
27 analysts
$76.00
161.08% Upside
-14.9%
VKTX
Viking Therapeutics
Jun 26, 2025 BUY Strong Buy
+141.0% avg upside
30 analysts
$102.00
236.03% Upside
+5.2%
KURA
Kura Oncology
Jun 04, 2025 HOLD Strong Buy
+170.6% avg upside
26 analysts
$8.00
16.44% Downside
+36.0%
AURA
Aura Biosciences Inc
May 16, 2025 BUY Strong Buy
+238.0% avg upside
9 analysts
$23.00
268.79% Upside
+30.1%
TPST
Tempest Therapeutics
May 14, 2025 HOLD Buy
+1646.8% avg upside
18 analysts
$9.00
619.92% Upside
-68.1%
ADAPY
Adaptimmune Therapeutics
May 14, 2025 BUY Buy
+5717.9% avg upside
10 analysts
$1.40
3399.97% Upside
·
ABSI
AbSci
May 14, 2025 BUY Strong Buy
+40.1% avg upside
18 analysts
$13.00
79.49% Upside
+90.4%
CGON
CG Oncology, Inc.
May 14, 2025 HOLD Strong Buy
+42.0% avg upside
17 analysts
$23.00
62.07% Downside
+187.7%
TARA
Protara Therapeutics
May 09, 2025 BUY Strong Buy
+1134.8% avg upside
21 analysts
$12.00
195.53% Upside
+62.6%
SKYE
Skye Bioscience
May 09, 2025 BUY Strong Buy
+1327.3% avg upside
9 analysts
$20.00
2610.41% Upside
-52.5%
ARVN
Arvinas Holding Company
Dec 14, 2020 BUY Buy
+266.4% avg upside
27 analysts
$114.00
1405.86% Upside
-22.5%
CCCC
C4 Therapeutics
Dec 08, 2020 BUY Strong Buy
+354.5% avg upside
19 analysts
$45.00
1053.89% Upside
+12.7%
PTGX
Protagonist Therapeutics
Dec 07, 2020 BUY Strong Buy
-21.5% avg upside
19 analysts
$46.00
58.86% Downside
+47.6%
MRNA
Moderna
Nov 17, 2020 HOLD Hold
+9.4% avg upside
38 analysts
$109.00
73.48% Upside
+160.0%
INCY
Incyte
Nov 06, 2020 HOLD Buy
+1.0% avg upside
47 analysts
$87.00
9.60% Downside
-18.4%
EXEL
Exelixis
Sep 21, 2020 HOLD Strong Buy
-21.4% avg upside
33 analysts
$27.00
47.24% Downside
-21.2%
BBIO
BridgeBio Pharma
Aug 12, 2020 BUY Strong Buy
+36.6% avg upside
34 analysts
$44.00
33.12% Downside
+76.0%
IMUX
Immunic
Aug 03, 2020 BUY Strong Buy
+166.9% avg upside
21 analysts
$61.00
332.25% Upside
-58.9%
AGIO
Agios Pharma
Dec 09, 2019 BUY Strong Buy
+78.4% avg upside
29 analysts
$49.00
45.94% Upside
-19.5%
NKTR
Nektar Therapeutics
Nov 11, 2019 BUY Buy
+18.4% avg upside
25 analysts
$46.00
23.35% Downside
-18.4%
EDIT
Editas Medicine
May 08, 2019 BUY Buy
+434.5% avg upside
33 analysts
$40.00
1438.47% Upside
-1.7%
MDGL
Madrigal Pharmaceuticals
Feb 23, 2012 BUY Strong Buy
-4.7% avg upside
31 analysts
$8.00
98.36% Downside
+65.6%
VRTX
Vertex Pharmaceuticals
Feb 03, 2012 HOLD Strong Buy
-3.9% avg upside
61 analysts
$34.00
92.50% Downside
+23.5%
TCRT
Alaunos Therapeutics
Nov 10, 2011 BUY Buy
+582.8% avg upside
13 analysts
$9.00
310.04% Upside
+7.1%
OSIS
OSI Systems
Mar 02, 2010 HOLD Strong Buy
+0.6% avg upside
11 analysts
+24.2%
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
George Farmer — Frequently Asked Questions
How accurate are George Farmer's stock ratings?
Based on the calls 13Foresight could measure, about 61% of George's ratings were profitable over a one-year hold, with an average return of +22.4% per rating, or -1.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is George ranked on 13Foresight?
George Farmer is currently ranked #1221 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does George cover?
George most recently has ratings on NAMS, BMEA, URGN, SNDX, BMRN, BIIB, ARGX, INMB, JANX, LEGN, VKTX, KURA and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.